Rainier Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

SAN LEANDRO, Calif., February 21, 2019 — Rainier Therapeutics, Inc., a privately-held
clinical stage drug development company, today announced that Scott Myers, Chairman and
Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare
Conference on Wednesday, February 27, 2019 at 1:30 p.m. ET (10:30 a.m. PT) at the Lotte
New York Palace in New York City.

About Rainier Therapeutics
Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing
a targeted biologic for the potential treatment of metastatic bladder cancer. The company’s
antibody, vofatamab (formerly B-701), is focused specifically on the fibroblast growth factor
receptor 3 (FGFR3), a known driver of bladder and other cancers. For more information,
please visit www.rainierrx.com.

Contacts:
Robert Uhl
Westwicke
(858) 356-5932
Robert.uhl@westwicke.com

Julie Rathbun
Rathbun Communications
(206) 769-9291
julie@rathbuncomm.com